Laden.... Wacht alsjeblieft even.
Bedrijfsprofiel
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases.
Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Bron:
Cofisem
-
laatste update:
29 Mar 2025
Bestuurders
| Chief Executive Officer | Marc Garidel | ||||
| Administrative & Finance Director | Didier Blondel | ||||
| Chief Business Development Officer | Pierre Courteille | ||||
| Chief Compliance Officer | Ida Hatoum | ||||
| Chief Human Resources Officer | Ida Hatoum | ||||
| Chief Scientific Officer | Didier Scherrer | ||||
| Strategy Director | David Zhang | ||||
| Head of Investor Relations | Patrick Malloy | ||||
| Bron: Cofisem - laatste update: 29 Mar 2025 | |||||
Kerncijfers
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 0 | 0 | 0 | 0 | |
| Income from ordinary activities | 0 | 0 | 0 | ||
| Operating income | -172.984 | -127.376 | -64.836 | -41.400 | |
| Cost of financial indebtedness net | 4.185 | 11.408 | 6.939 | 3.559 | |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | -176.242 | -147.740 | -60.740 | -42.452 | -37.551 |
| Net income (Group share) | -176.242 | -147.740 | -60.740 | -42.452 | |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | French_GAAP |
| Consumed purchases | 1 | ||||
| Labour costs | 5.600 | ||||
| Operating profit | -38.008 | ||||
| Income tax | -2.575 | ||||
| Net consolidated income (Group share) | -37.551 | ||||
| Bron: Cofisem - laatste update: 29 Mar 2025 | |||||
Adres
Abivax
7-11 Boulevard Haussmann
FR-75009
Paris
France
Telefoonnummer:
+33 (0)1 53 83 08 41
Bron:
Cofisem
-
laatste update:
29 Mar 2025